Oncimmune Inks Deal With Accu Reference to Offer EarlyCDT-Lung Test | GenomeWeb

NEW YORK (GenomeWeb) – UK-based diagnostics firm Oncimmune said today that it has signed an agreement with US clinical laboratory Accu Reference for the firm to offer Oncimmune's EarlyCDT-Lung test to physicians.

The EarlyCDT-Lung test measures levels of seven autoantibodies in patient blood to aid in the early detection of lung cancer. Oncimmune markets the test both for detecting lung cancer before it can be picked up via imaging techniques like CT scans and for helping to evaluate whether nodules detected via imaging are likely malignant or benign.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.